SUPPLEMENTAL DATA - Tertiary Screen of 38 Compounds

compounds	% survival at 10 µM	MTDcc (µM)	% suppression of GFAP promoter	supplier
diaziquone	80	>20	86	SA
clomipramine	83	12.5	66	SA
chrysophanol	86	12.5	66	SA
amitriptyline	102	> 20	63	SA
chlorprothixene	79	17.5	60	SA
EGCDG	84	17.5	57	MS
tamoxifen citrate	60	7.5	52	SA
mundoserone	88	>20	50	MS
amlodipine	98	12.5	44	SA
embelin	63	7.5	37	SA
thioridazine	32	5	37	SA
ritanserin	88	12.5	29	SA
irigenol	71	>20	28	MS
fluocinonide	101	>20	28	IBS
hexetidine	108	>20	26	SA
estradiol benzoate	78	>20	26	CC
ketotifen	108	>20	25	SA
clobetasol propionate	103	>20	25	SA
colecalciferol	80	>20	24	SA
fluphenazine	65	7.5	23	SA
pyrogallin	75	>20	22	MS
kanamycin	138	>20	22	SA
azinphos methyl	105	>20	18	SA
acetaminosalol	96	>20	17	MS
oxotremorine	116	>20	16	SA
ritodrine	120	>20	16	SA
NPPB	107	>20	16	SA
chloramphenicol	106	>20	16	SA
terfenadine	16	2.5	14	SA
phosphocreatine	86	>20	13	SA
betulinic acid	102	>20	13	SA
methylnorlichexanthone	95	>20	10	MS
coumophos	92	>20	10	MS
swietenolide-3-acetate	95	>20	8	MS
dacarbazine	87	>20	7	SA
veratric acid	85	>20	6	SA
pantothenic acid	75	>20	6	SA
neamine	73	>20	5	SA

Table 2. Thirty-eight compounds analyzed in tertiary screen, sorted by degree of suppression of GFAP promoter. A dose-response association was evaluated after exposure to each compound at various concentrations (0.1, 0.5, 1, 5, 10, 15, 20 µM) for 48 hrs. The "maximum tolerable dose" (MTDcc) indicates the highest concentration that reduced cell viability < 30%. Each compound and concentration was analyzed in quadruplicate wells. EGCDG: epigallocatechin 3,5-digallate. *Supplier abbreviations are as follows: SA (Sigma Aldrich), MS (Microsource Spectrum), IBS (Interbioscreen, Inc.), CC (Cayman Chemical).*